Correction: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Le Qin(Chinese Academy of Sciences), Peng Li(Chinese Academy of Sciences), Jianyu Weng(Guangdong General Hospital), Baiheng Li(Chinese Academy of Sciences), Xin Du, Duanqing Pei(Westlake University), Yunxin Lai(First Affiliated Hospital of Guangzhou Medical University), Peilong Lai(Guangdong General Hospital), Qiting Wu(Chinese Academy of Sciences), Yangqiu Li(Jinan University), Ruocong Zhao(Chinese Academy of Sciences), Yao Yao(Dalian Medical University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Simiao Lin(Chinese Academy of Sciences), Suna Wang(National Institutes of Health), Xinru Wei(China Energy Engineering Corporation (China)), Qiubin Liang(Guangzhou Institutes of Biomedicine and Health), Xuchao Zhang(Guangdong General Hospital), Pentao Liu(Hong Kong Science and Technology Parks Corporation)
Cited by 1
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k